Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
In the footnotes

What the 10-K filed Feb 24, 2026 says off the balance sheet

10-K notes
Topics with specifics 3 of 6 with a sentence that gives amounts, accruals or ratios
Sentences quoted 10 word for word, each linked to the 10-K
New this year 4 sentences with nothing like them in the 10-K filed Feb 26, 2025

Risks that are not on the face of the balance sheet. Tickdelta picks sentences with specifics and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed Feb 26, 2025.

Big customers

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

No specific sentence about this in the 10-K.

Key suppliers

Parts or manufacturing that depend on one or a few suppliers.

1 new

New “HHS has also been empowered to negotiate the price of certain single-source drugs that have been on the market for at least 7 years covered under Medicare as part of the Medicare Drug Price Negotiation Program.”

Read it in the 10-K

“In part due to the limited market size for our products and product candidates, we have a single source of supply for most of our marketed products, product candidates and their APIs.”

Read it in the 10-K

“Zepzelca is manufactured by Simtra, which is a sole source supplier from a single site location.”

Read it in the 10-K

“Vyxeos is manufactured by Simtra, which is a sole source supplier from a single site location.”

Read it in the 10-K

Lawsuits and legal claims

Pending cases, settlements and what the company has set aside for them.

3 new

New “We have settled patent litigation with each of the ten companies seeking to market a generic version of Epidiolex in the U.S. by granting each of the Epidiolex ANDA Filers a license to manufacture, market, and sell its own generic version of Epidiolex beginning in the very late 2030s, or earlier under certain circumstances, including but not limited to the launch of another generic Epidiolex product or a final decision that all unexpired claims of the Epidiolex patents are not infringed, or are invalid and/or unenforceable.”

Read it in the 10-K

“In addition, business practices by pharmaceutical companies, including product formulation improvements, patent litigation settlements, and REMS programs, have increasingly drawn public scrutiny from legislators and regulatory agencies, with allegations that such programs are used as a means of improperly blocking or delaying competition.”

Read it in the 10-K

New “Selling, general and administrative expenses increased in 2025 compared to 2024, primarily due to Xyrem antitrust litigation settlements of $233.5 million, the Avadel litigation settlement of $90.0 million and an increase in compensation-related expenses of $96.7 million, primarily driven by higher headcount and increased share-based compensation expense, increased investment in sales and marketing of $21.9 million in support of our commercial portfolio, and included integration expenses related to the Chimerix Acquisition of $19.4 million.”

Read it in the 10-K

“Selling, general and administrative expenses increased in 2024 compared to 2023, primarily due to increased compensation-related expenses of $72.6 million, primarily driven by higher headcount and increased investment in sales and marketing of $19.3 million, in support of our commercial portfolio and increased litigation costs of $13.6 million, partially offset by costs relating to the impairment of facility assets of $61.7 million and program terminations of $23.5 million incurred in 2023.”

Read it in the 10-K

New “Net cash provided by operating activities decreased by $40.1 million in 2025 compared to 2024, primarily due to the payment of $323.5 million in litigation settlement expenses in 2025, partially offset by cash received from increased sales of our products and the timing of payment of accrued expenses.”

Read it in the 10-K

Guarantees and indemnities

Promises to pay someone else's debts or losses if they cannot.

No specific sentence about this in the 10-K.

Debt covenants

Conditions in loan agreements that, if broken, can make debt due early.

No specific sentence about this in the 10-K.

Commitments off the balance sheet

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

“Our long-term noncancelable purchase commitments were $30.6 million at December 31, 2025, primarily related to agreements with third party manufacturers.”

Read it in the 10-K
Customers it names 0 tracked companies its filings call a customer
Suppliers it names 0 tracked companies its filings call a supplier
Companies that name it 0 tracked companies whose filings call it a customer or a supplier

Companies it names

Tracked companies that its latest 10-K or its 8-Ks of the last year call a customer or a supplier.

No other tracked company is named as a customer or a supplier in the latest filings.

Companies that name it

Tracked companies whose latest 10-K or 8-Ks call it a customer or a supplier.

No other tracked company names it as a customer or a supplier in the latest filings.

Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K

Sources

The notes to the financial statements, Legal Proceedings and the MD&A of the latest 10-K (and, for customers and suppliers, Business and Risk Factors), quoted as filed.

Also

Debt: the debt note in numbers.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:Reverse DCF
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.